目的:分析p53、PKD1和MAP2K4在子宫内膜癌(EC)患者血清中的表达及其预后价值。
方法:将2018年1月至2020年1月在我院接受治疗的84例EC患者纳入研究组。同时有50名健康个体被纳入对照组进行回顾性分析。qRT-PCR用于定量对照组和研究组(在癌症和癌旁组织中)血清中p53,PKD1和MAP2K4的相对水平。分析p53、PKD1和MAP2K4与EC病理特征的相关性。随访1年,观察患者死亡情况,分析p53、PKD1、MAP2K4与EC预后的关系。
结果:EC患者p53和MAP2K4水平低,PKD1水平高(P<0.05)。血清中p53、MAP2K4和PKD1水平与EC分化有关。FIGO阶段,淋巴结转移,和深肌层浸润(P<0.05)。在预后随访期间,死亡患者的血清p53和MAP2K4水平低于存活患者。PKD1在原发患者中明显高于原发患者(P<0.05)。
结论:在EC中p53和MAP2K4的低表达和PKD1的高表达与疾病的进展有关。这些表达有助于有效评估患者的预后和生存。它们对未来的诊断和治疗具有重要的研究和参考意义。
OBJECTIVE: To analyze the p53, PKD1, and
MAP2K4 expressions in serum of patients with endometrial carcinoma (EC) and their prognostic value.
METHODS: A total of 84 patients with EC who were treated in our hospital between January 2018 and January 2020 were enrolled into a research group. There were 50 healthy individuals over the same time who were included in a control group for a retrospective analysis. qRT-PCR was used for quantifying the relative levels of p53, PKD1, and MAP2K4 in the serum of the control group and the research groups (in both cancer and paracancerous tissues). The associations of p53, PKD1, and
MAP2K4 with pathological features of EC were analyzed. Patients were followed up for 1 year to observe their death and analyze the associations of p53, PKD1, and MAP2K4 with prognosis of EC.
RESULTS: The patients with EC had low p53 and
MAP2K4 levels and high PKD1 levels (P<0.05). The p53,
MAP2K4, and PKD1 levels in serum were relevant to EC differentiation, FIGO stage, lymph node metastasis, and deep myometrial invasion (P<0.05). During the follow-up of prognosis, the serum levels of p53 and MAP2K4 in dead patients were lower than those in surviving patients. PKD1 in former patients was higher (P<0.05).
CONCLUSIONS: The low expressions of p53 and
MAP2K4 and high expression of PKD1 in EC cases were related with disease progression. These expressions can help effectively evaluate the prognosis and survival of patients. They are of crucial research and reference significance for future diagnosis and therapy.